Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
69.00
-0.80 (-1.15%)
At close: Mar 26, 2026

Handa Pharmaceuticals Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
10,85610,57625,89116,0748,4512,820
Market Cap Growth
-16.34%-59.15%61.07%90.20%199.72%-18.91%
Enterprise Value
8,2908,08523,74715,8698,2492,326
Last Close Price
69.0073.58179.00118.6165.8623.12
PE Ratio
15.2222.3735.62---
PS Ratio
6.7112.7323.4081.32289.0897.71
PB Ratio
2.423.399.3922.2918.255.23
P/TBV Ratio
2.934.899.5223.4619.805.59
P/FCF Ratio
61.8021.5938.79---
P/OCF Ratio
55.8821.2538.74---
EV/Sales Ratio
5.139.7321.4780.28282.1580.61
EV/EBITDA Ratio
8.3519.2034.00---
EV/EBIT Ratio
9.5619.3434.25---
EV/FCF Ratio
47.2016.5135.58---
Debt / Equity Ratio
0.010.010.010.040.030.03
Debt / EBITDA Ratio
0.050.090.02---
Debt / FCF Ratio
0.280.080.02---
Net Debt / Equity Ratio
-0.57-0.57-0.84-0.47-0.59-0.56
Net Debt / EBITDA Ratio
-2.61-4.25-3.304.141.110.98
Net Debt / FCF Ratio
-14.61-3.65-3.451.591.470.96
Asset Turnover
-0.260.580.310.050.04
Quick Ratio
32.258.4912.8911.6310.059.05
Current Ratio
32.448.7212.9613.0710.5710.79
Return on Equity (ROE)
-16.10%41.81%-6.76%-49.43%-41.47%
Return on Assets (ROA)
-8.07%22.64%-8.54%-29.36%-27.20%
Return on Invested Capital (ROIC)
41.24%46.33%151.89%-30.57%-118.36%-143.32%
Return on Capital Employed (ROCE)
18.80%13.10%24.50%-11.80%-54.20%-58.30%
Earnings Yield
6.29%4.47%2.81%-0.25%-2.93%-10.00%
FCF Yield
1.62%4.63%2.58%-1.32%-2.19%-11.20%
Dividend Yield
2.16%2.04%0.56%---
Payout Ratio
34.59%29.84%----
Buyback Yield / Dilution
-6.72%-4.73%-7.29%-6.65%-1.87%-5.35%
Total Shareholder Return
-4.55%-2.69%-6.73%-6.65%-1.87%-5.35%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.